Roche Hldg Ltd Spons (RHHBY) 35.9500 $RHHBY
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
Synageva's Q1 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:10PM CDT
Synageva (GEVA) posts narrower-than-expected loss in the first quarter of 2014.
Novo Nordisk Q1 Revenue Misses; Guidance Lowered
at Investor's Business Daily - Thu May 01, 10:48AM CDT
Danish pharmaceutical giant Novo Nordisk (NVO) missed Q1 sales estimates and lowered its full-year revenue forecast Thursday, though profit was in line. Novo stock was down more than 2% in early trading on the stock market today. Novo made 45 cents a...
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Label Expansion for Roche's HPV Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 4:30PM CDT
Roche (RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved its cobas Human Papillomavirus (HPV) Test for use as a first-line primary screening test for cervical cancer in women aged 25 and above.
OTC Markets Group Announces First Quarter 2014 Performance of OTCM ADR Index
PR Newswire - Mon Apr 28, 3:10PM CDT
OTC Markets Group Inc. (OTCQX: OTCM) today announced the OTCM ADR Index powered by BNY Mellon DR IndicesSM (Bloomberg/Reuters: OTCDR; Thomson: DFCDR), the only index exclusively tracking American Depositary Receipts ("ADRs"
trading on the OTCQX®, OTCQB® and OTC Pink® marketplaces, declined slightly by (-0.13%) in the first quarter 2014. Despite this, the total dollar volume of ADRs in the Index rose 29% to a record $33.86 billion during the quarter.
In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 11:33AM CDT
Antibody-drug conjugate developer ImmunoGen reported disappointing third-quarter earnings results before the opening bell this morning, delivering a decline in revenue, a considerably wider loss, and lowering its outlook for the year. For the...
Global Home Healthcare Market Forecasts & Opportunities, 2018
M2 - Thu Apr 24, 7:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld8xpj/global_home) has announced the addition of the "Global Home Healthcare Market (2013 - 2018)" report to their offering. The home healthcare equipment and services market is predicted to grow to between 6% to 8% year on year for the next five years. The market is estimated to reach $345 billion by 2020. The demand for home healthcare services is growing at a steady pace across the globe. Increasing costs of in-hospital care and the comfort of convalescing at home are making home healthcare affordable and desirable in both developed and developing nations. Better and cheaper medical devices have moved the diagnosis of various ailments from hospitals to the living room. People suffering from chronic ailments such as cardiovascular diseases, cancer, respiratory diseases and diabetes prefer home healthcare services. The services for geriatric ailments, physical, occupational and speech therapies, and personal care are rapidly becoming a necessity more than luxury. Currently, over 70% of those using home healthcare services belong to the age group of 65-75 years or older. The World Bank estimates that by 2050, close to 21% of the world population will be over 60 years old, making home healthcare a key sector to be followed. The market in Asia for healthcare equipment alone is set to grow from $3bn currently to $11 bn by 2016. This presents a huge growth opportunity for Home Healthcare providers who are looking for opportunities in countries other than the U.S where the growth is almost stable, but tied to reimbursements from Medicare and Medic-aid policies. Developing countries like India are the high-growth regions. Many players have already started cashing in on this opportunity. The US-based BAYADA Home Healthcare has recently acquired a 26% stake in India-based Indian Home Healthcare (IHHC). The home healthcare market is an aggregate of home health products and services. Awareness about the convenience and cost effectiveness offered by these products and services is also increasing the demand for this market. Advanced economies also maintain a stable growth mainly due to reimbursements offered for specific equipment and health policies of government and private entities. Portability, customization, ease of use, and automation are the key factors that home healthcare market players use to differentiate their products and services. Scope Products - Dialysis - Diabetes - Drug Delivery - Essential - Mobility - Respiratory - Others Services - Rehabilitation - Skilled - Unskilled - Virtual - Hospice - Companion - Social - Others Key Topics Covered: 1. Global Home Healthcare - Market Overview 2. Executive Summary 3. Global Home Healthcare - Market Landscape 4. Global Home Healthcare - Market Forces 5. Global Home Healthcare Market - Strategic Analysis 6. Home Healthcare Services Market 7. Home Healthcare Market - By Type of Aliment / Disease / Problem 8. Home Healthcare Products / Equipment Market 9. Geographic Analysis 10. Market Entropy 11. Investment Opportunities - Analysis by Target companies/customers, Capital Investments, ROI, Payback Period and Source of Funds. 12. Company Profiles - A&D Company, Ltd. - Abbott Laboratories - Alere, Inc. - Almost Family, Inc. - Apria Healthcare Group, Inc. - Baxter International, Inc. - Bayer Ag - Braun Melsungen Ag. - C.R Bard - Cardinal Health, Inc. - Covidien Ltd. - Fresenius Se & Co Kgaa - Fisher & Paykel Healthcare - Ge Healthcare - Gentiva Health Services Inc. - I-Flow - Icon Health & Fitness, Inc. - Invacare - Johnson & Johnson - Kinetic Concepts, Inc. - Lhc Group, Inc. - Linde Group - Nestle S.A. - Omron Healthcare Co., Ltd. - Philips Healthcare - Photomedex, Inc. - Res Med - Roche Holding Ag - Smiths Group Plc - Sunrise Medical For more information visit http://www.researchandmarkets.com/research/ld...lobal_home About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Roche Launches Kadcyla in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 6:00PM CDT
Roche's breast cancer franchise received a boost when it announced that it has launched its cancer drug Kadcyla in Japan.
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
High Hopes for Ketamine Depression Treatments
at The Street - Thu Apr 17, 8:45AM CDT
Does a recreational drug and horse tranquilizer really have potential as an effective treatment for one of the toughest, and most common, psychiatric illnesses out there?
Abbott Labs Earnings: Still Marking Time
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
Like many other large med-tech companies, Abbott Labs remains an exercise in frustration right now. There are pressures throughout most of the company's business lines, with only the diagnostics business really showing much growth. Although...
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why ImmunoGen Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:13PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ImmunoGen , a biopharmaceutical company...
Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion
Isis Pharma's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 3:30PM CDT
Isis Pharma (ISIS) reported wider-than-expected loss in the first quarter of 2014.
Synageva's Q1 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:10PM CDT
Synageva (GEVA) posts narrower-than-expected loss in the first quarter of 2014.
Novo Nordisk Q1 Revenue Misses; Guidance Lowered
at Investor's Business Daily - Thu May 01, 10:48AM CDT
Danish pharmaceutical giant Novo Nordisk (NVO) missed Q1 sales estimates and lowered its full-year revenue forecast Thursday, though profit was in line. Novo stock was down more than 2% in early trading on the stock market today. Novo made 45 cents a...
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Label Expansion for Roche's HPV Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 4:30PM CDT
Roche (RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved its cobas Human Papillomavirus (HPV) Test for use as a first-line primary screening test for cervical cancer in women aged 25 and above.
OTC Markets Group Announces First Quarter 2014 Performance of OTCM ADR Index
PR Newswire - Mon Apr 28, 3:10PM CDT
OTC Markets Group Inc. (OTCQX: OTCM) today announced the OTCM ADR Index powered by BNY Mellon DR IndicesSM (Bloomberg/Reuters: OTCDR; Thomson: DFCDR), the only index exclusively tracking American Depositary Receipts ("ADRs"
trading on the OTCQX®, OTCQB® and OTC Pink® marketplaces, declined slightly by (-0.13%) in the first quarter 2014. Despite this, the total dollar volume of ADRs in the Index rose 29% to a record $33.86 billion during the quarter. In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 11:33AM CDT
Antibody-drug conjugate developer ImmunoGen reported disappointing third-quarter earnings results before the opening bell this morning, delivering a decline in revenue, a considerably wider loss, and lowering its outlook for the year. For the...
Global Home Healthcare Market Forecasts & Opportunities, 2018
M2 - Thu Apr 24, 7:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld8xpj/global_home) has announced the addition of the "Global Home Healthcare Market (2013 - 2018)" report to their offering. The home healthcare equipment and services market is predicted to grow to between 6% to 8% year on year for the next five years. The market is estimated to reach $345 billion by 2020. The demand for home healthcare services is growing at a steady pace across the globe. Increasing costs of in-hospital care and the comfort of convalescing at home are making home healthcare affordable and desirable in both developed and developing nations. Better and cheaper medical devices have moved the diagnosis of various ailments from hospitals to the living room. People suffering from chronic ailments such as cardiovascular diseases, cancer, respiratory diseases and diabetes prefer home healthcare services. The services for geriatric ailments, physical, occupational and speech therapies, and personal care are rapidly becoming a necessity more than luxury. Currently, over 70% of those using home healthcare services belong to the age group of 65-75 years or older. The World Bank estimates that by 2050, close to 21% of the world population will be over 60 years old, making home healthcare a key sector to be followed. The market in Asia for healthcare equipment alone is set to grow from $3bn currently to $11 bn by 2016. This presents a huge growth opportunity for Home Healthcare providers who are looking for opportunities in countries other than the U.S where the growth is almost stable, but tied to reimbursements from Medicare and Medic-aid policies. Developing countries like India are the high-growth regions. Many players have already started cashing in on this opportunity. The US-based BAYADA Home Healthcare has recently acquired a 26% stake in India-based Indian Home Healthcare (IHHC). The home healthcare market is an aggregate of home health products and services. Awareness about the convenience and cost effectiveness offered by these products and services is also increasing the demand for this market. Advanced economies also maintain a stable growth mainly due to reimbursements offered for specific equipment and health policies of government and private entities. Portability, customization, ease of use, and automation are the key factors that home healthcare market players use to differentiate their products and services. Scope Products - Dialysis - Diabetes - Drug Delivery - Essential - Mobility - Respiratory - Others Services - Rehabilitation - Skilled - Unskilled - Virtual - Hospice - Companion - Social - Others Key Topics Covered: 1. Global Home Healthcare - Market Overview 2. Executive Summary 3. Global Home Healthcare - Market Landscape 4. Global Home Healthcare - Market Forces 5. Global Home Healthcare Market - Strategic Analysis 6. Home Healthcare Services Market 7. Home Healthcare Market - By Type of Aliment / Disease / Problem 8. Home Healthcare Products / Equipment Market 9. Geographic Analysis 10. Market Entropy 11. Investment Opportunities - Analysis by Target companies/customers, Capital Investments, ROI, Payback Period and Source of Funds. 12. Company Profiles - A&D Company, Ltd. - Abbott Laboratories - Alere, Inc. - Almost Family, Inc. - Apria Healthcare Group, Inc. - Baxter International, Inc. - Bayer Ag - Braun Melsungen Ag. - C.R Bard - Cardinal Health, Inc. - Covidien Ltd. - Fresenius Se & Co Kgaa - Fisher & Paykel Healthcare - Ge Healthcare - Gentiva Health Services Inc. - I-Flow - Icon Health & Fitness, Inc. - Invacare - Johnson & Johnson - Kinetic Concepts, Inc. - Lhc Group, Inc. - Linde Group - Nestle S.A. - Omron Healthcare Co., Ltd. - Philips Healthcare - Photomedex, Inc. - Res Med - Roche Holding Ag - Smiths Group Plc - Sunrise Medical For more information visit http://www.researchandmarkets.com/research/ld...lobal_home About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Roche Launches Kadcyla in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 6:00PM CDT
Roche's breast cancer franchise received a boost when it announced that it has launched its cancer drug Kadcyla in Japan.
Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
High Hopes for Ketamine Depression Treatments
at The Street - Thu Apr 17, 8:45AM CDT
Does a recreational drug and horse tranquilizer really have potential as an effective treatment for one of the toughest, and most common, psychiatric illnesses out there?
Abbott Labs Earnings: Still Marking Time
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
Like many other large med-tech companies, Abbott Labs remains an exercise in frustration right now. There are pressures throughout most of the company's business lines, with only the diagnostics business really showing much growth. Although...
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:26PM CDT
If you haven't noticed, earnings season is starting to kick into full swing, and investors apparently like what they're seeing thus far, with the broad-based S&P 500 surging to its third consecutive gain. In addition to a number of positive...
Why ImmunoGen Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 12:13PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ImmunoGen , a biopharmaceutical company...
Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion
